- 期刊
Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
被引用紀錄
張琇涵（2014）。DPP-4 抑制劑 Linagliptin對抗β類澱粉蛋白導致神經毒性之保護作用〔碩士論文，中山醫學大學〕。華藝線上圖書館。https://doi.org/10.6834/CSMU.2014.00167
延伸閱讀
- 楊宗元（2016）。Sitagliptin and Risk of Cardiovascular Disease in Type 2 Diabetes Mellitus〔博士論文，中山醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0003-0808201615561100
- Kim, S. H., Yoon, S. Y., Lim, S. K., & Rhee, Y. M. (2014). The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes. International Journal of Endocrinology, 2014(), 596-600-163. https://doi.org/10.1155/2014/715908
- Kim, M. J., & Lim, Y. (2013). Protective Effect of Short-Term Genistein Supplementation on the Early Stage in Diabetes-Induced Renal Damage. Mediators of Inflammation, 2013(), 814-827-173. https://doi.org/10.1155/2013/510212
- Leu, J. G., Huang, M. M., Pai, J. K., & Jiang, W. W. (2005). Efficacy and Safety of 20 mg/day Simvastatin in Patients with Renal Impairment and Combined Hyperlipidemia. 輔仁醫學期刊, 3(1), 43-47. https://www.airitilibrary.com/Article/Detail?DocID=18102093-200506-3-1-43-47-a
- 楊璦瑜（2020）。Clinical Effectiveness and Safety of Dapagliflozin as Add-On Therapy for Patients With Type 2 Diabetes。臺灣臨床藥學雜誌，28(2)，129-137。https://doi.org/10.6168/FJCP.202004_28(2).0006